CD19 and diffuse large B-cell lymphoma: However, in the JULIET study testing tisagenlecleucel in DLBCL, similar treatment responses were observed in patients with normal versus low/absent CD19 expression as determined by quantitative immunofluorescence (16), suggesting that accurate determination of CD19 expression levels may not be required when considering eligibility for CART19 therapy.